|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Also, CD4, CD8, and CD56 staining were performed to investigate the Immulina® effect on the immune cells' recruitment to the tumors by immunohistochemistry.
|
31691383 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, we identified an NK cell-related CD56+ ILC population involved in tumor immunosurveillance in humans, and we propose that restoring their functions with anti-NKG2A antibodies and/or small molecules inhibiting TGF-β1 might represent a novel strategy for improving current immunotherapies.
|
31765481 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting the progenitor blastoma and these transitions with an anti-NCAM1 immunoconjugate (Lorvotuzumab mertansine) inhibited tumor growth and progression providing new paradigms for PPB therapeutics.
|
31477684 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This SCMCIE94 protocol had been used in almost all the patients described in an earlier report, in whom those with non-pelvic isolated tumors and low/absent CD56 expression in Ewing sarcoma tumor cells were all long-term survivors.
|
30770960 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report the case of an ovarian large cell carcinoma expressing all neuroendocrine markers (CD56, chromogranin A, synaptophysin) that presented as a primary tumor and coexisted with a typical endometrial serous carcinoma also expressing one neuroendocrine marker (CD56).
|
30171991 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The levels of CgA, synaptophysin and neural cell adhesion molecule 1 in the tumour tissue were assessed by immunohistochemical assays.
|
30675205 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunostain for achaete-scute homolog 1, chromogranin, synaptophysin, and CD56 supported the NE and/or neuroepithelial differentiation of the tumors.
|
30523500 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry analysis of the tumor tissue showed CK5/6 (+), p63 (+), CD56 (+), and Ki-67 (+, approximately 30%), and genetic testing detected no <i>EGFR</i> mutation.
|
31417937 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the tumor was positive for pancytokeratin (AE1/AE3), S-100 protein and CD56, while it was negative for glial fibrillary acid protein, thyroid transcription factor-1, epithelial membrane antigen, other cytokeratins and pituitary hormones.
|
31373070 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pathologists should be aware that YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma is commonly positive with CD56 and CD99; as well as potentially assisting in diagnosis, positivity with these markers may also result in consideration of other neoplasms in the differential diagnosis.
|
30252726 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
K7-positive, Κ19-positive and CD56-positive ductular structures were encountered within the metastatic tumour (tumour interior and periphery), and in the immediate peritumoral area.
|
29220096 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The immunohistochemical results were as follows: the tumour cells were positive for FGF23 (nine of 12, 75%), FGFR1 (11 of 11, 100%), CD56 (12 of 14, 85.7%) and E26 oncogene homologue (ERG) (5 of 13, 38.4%).
|
28858396 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor displayed CD56, chromogranin-A, and synaptophysin immunoreactivity.
|
29533277 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Positivity for p16 in combination with chromogranin and CD56 may be potentially good markers for differentiating this tumor from other adnexal tumors.
|
29533280 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Pathology revealed spindle cell tumour with extensive expression of S100 protein and CD56, with Ki-67 proliferation index of 1%-2% consistent with benign schwannoma.
|
29848524 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The CD56 antigen (NCAM-1) is highly expressed on several malignancies with neuronal or neuroendocrine differentiation, including small-cell lung cancer and neuroblastoma, tumor types for which new therapeutic options are needed.
|
29622795 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This case indicated that EP should be considered as a differential diagnosis even when a tumor shows large cell morphology and is positive for CD3, CD56, and EBER1.
|
29572766 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we describe the design, synthesis, physico-chemical characterization and the biological evaluation of an NCAM-targeted conjugate of polyglutamic acid with paclitaxel that was developed and evaluated on neuroblastoma, a high NCAM-expressing tumor.
|
28159518 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, CD56 immunoreactivity by itself can be found in a broad variety of tumors, including ovarian neoplasms.
|
27984374 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD56+ natural killer-cell populations were measured by immunohistochemistry and found to be significantly higher in tumor regression grade 3 patients compared with tumor regression grade 1-2 in the validation cohort.
|
28621318 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Infiltration of CD10(+), CD20(+), CD56(+) or CD138(+) cells was not revealed in all tumors.
|
28454377 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).
|
28349943 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Coupled with its low incidence rate, the disease has experienced a number of name changes over the past three decades (e.g., blastic NK cell lymphoma, CD4+CD56+ hematodermic tumor), thereby historically resulting in difficulties in its clinico-pathologic diagnosis and treatment approaches.
|
29064025 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All BCCs showed patchy expression of CD56 except for 2 cases, which showed staining of greater than 70% of tumor.
|
28403527 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In tumorigenesis, NCAM1(+)CD133(-) marks SIX2(+) blastema that includes the ALDH1(+) WT cancer stem/initiating cells, while NCAM1(+)CD133(+) and NCAM1(-)CD133(+) specifying early and late epithelial differentiation, are severely restricted in tumor initiation capacity and tumor self-renewal.
|
27020553 |
2016 |